View More Recent Stories

Jun 14, 2017 09:56AM Viking Therapeutics (VKTX) Enters $4.3M Registered Direct Offering
Jun 14, 2017 09:55AM Viking Therapeutics Announces $4.3 Million Registered Direct Offering
Jun 6, 2017 07:15AM Viking Therapeutics (VKTX) Announces Top Line Results from In Vivo Study of VK2809 to Treat NASH
Jun 6, 2017 07:14AM Viking Therapeutics Announces Promising Top Line Results from In Vivo Study of VK2809 in Non-Alcoholic Steatohepatitis (NASH)
May 31, 2017 07:30AM Viking Therapeutics to Present at Upcoming Investor Conferences
May 10, 2017 04:05PM Viking Therapeutics Reports First Quarter 2017 Financial Results and Provides Corporate Update
May 3, 2017 07:30AM Viking Therapeutics to Report Financial Results for First Quarter 2017 After Market Close on May 10, 2017
Mar 28, 2017 07:30AM Viking Therapeutics to Present at H.C. Wainwright & Co.'s 1st Annual NASH Investor Conference
Mar 21, 2017 04:05PM Viking Therapeutics Reports Fourth Quarter and Year-End 2016 Financial Results and Provides Corporate Update
Mar 2, 2017 07:30AM Viking Therapeutics to Report Financial Results for Fourth Quarter and Year-End 2016 After Market Close on March 21, 2017
Feb 28, 2017 07:30AM Viking Therapeutics to Present at Upcoming Investor Conferences
Feb 14, 2017 07:09AM Viking Therapeutics (VKTX), PoC Capital Enter Agreement to Fund Development of VK2809 in GSD Ia
Feb 14, 2017 07:05AM Viking Therapeutics and PoC Capital Enter Agreement to Fund Clinical Development of VK2809 in Glycogen Storage Disease Ia (GSD Ia)
Feb 9, 2017 07:27AM Viking Therapeutics (VKTX) Reports Results form in Vivo Proof-of-Concept Study of VK2809 in GSD la
Feb 9, 2017 07:03AM Viking Therapeutics Announces Initial Results from In Vivo Proof-of-Concept Study of VK2809 in Glycogen Storage Disease Ia (GSD Ia)
Feb 7, 2017 07:30AM Viking Therapeutics to Present at 2017 BIO CEO & Investor Conference
Jan 5, 2017 04:48PM Viking Therapeutics Announces Senior Level Appointments to Management Team
Dec 21, 2016 07:30AM Viking Therapeutics to Present at Biotech Showcase 2017
Dec 6, 2016 04:10PM Viking Therapeutics (VKTX) Announces FDA Orphan Drug Designation for VK0214 to Treat X-ALD
Dec 6, 2016 04:05PM Viking Therapeutics Receives Orphan Drug Designation for VK0214 from the U.S. Food and Drug Administration for the Treatment of X-Linked Adrenoleukodystrophy
Nov 29, 2016 07:30AM Viking Therapeutics to Present at the LD Micro Main Event
Nov 15, 2016 07:03AM Viking Therapeutics (VKTX) Announces New, Statistically Significant Data from VK2809 Phasae 1b in Hypercholesterolemia
Nov 15, 2016 07:02AM Viking Therapeutics Presents New Clinical Data on VK2809 in Subjects with Elevated Cholesterol at American Heart Association Scientific Sessions 2016
Nov 10, 2016 04:05PM Viking Therapeutics Reports Third Quarter 2016 Financial Results and Provides Corporate Update
Nov 3, 2016 07:30AM Viking Therapeutics to Host Conference Call to Discuss Third Quarter 2016 Financial Results
Oct 13, 2016 07:30AM Viking Therapeutics to Present at the 2016 BIO Investor Forum
Oct 4, 2016 07:07AM Viking Therapeutics (VKTX) Announces Dosing of First Patient in VK2809 Phase 2
Oct 4, 2016 07:05AM Viking Therapeutics Doses First Patient in Phase 2 Clinical Trial of VK2809 in Patients with Hypercholesterolemia and Non-Alcoholic Fatty Liver Disease
Sep 26, 2016 07:06AM Viking Therapeutics (VKTX) Presents Data from VK0214 POC Study in X-ALD; Primary Objective Achieved
Sep 26, 2016 07:05AM Viking Therapeutics Presents Positive Proof-of-Concept Data for VK0214 in In Vivo Model of X-Linked Adrenoleukodystrophy (X-ALD) at the 86th Annual Meeting of the American Thyroid Association
Sep 7, 2016 07:00AM Viking Therapeutics to Present at Upcoming Investor Conferences
Sep 7, 2016 07:00AM Viking Therapeutics to Present at Upcoming Investor Conferences
May 24, 2016 10:24AM Notable Analyst Rating Changes 5/24: (SQ) (MSFT) (DE) Upgraded; (TWTR) (CF) (CYH) Downgraded
May 5, 2015 08:10AM Ligand Partner Viking Therapeutics Announces Closing of Initial Public Offering
View More Recent Stories